LYEL — Lyell Immunopharma Share News
0.000.00%
Last trade - 00:00- $230.10m
- $26.00m
- $0.04m
U.S. RESEARCH ROUNDUP-Intuit, Pioneer Natural Resources, Salesforce
Brief: Lyell Immunopharma Reports Business Highlights And Financial Results For The Fourth Quarter And Full Year 2022
Brief: Lyell Immunopharma Reports Recent Business Highlights, Third Quarter Financial Results
Lyell Immunopharma down on termination of GSK collaboration
Brief: Lyell Immunopharma-Glaxosmithkline Informed Co As Part Of Strategic Actions, It Is Discontinuing Development Of Product Candidates Targeting Ny-Eso-1
Lyell Immunopharma jumps after FDA permits human trials of cancer treatment
Brief: Lyell Immunopharma Announces FDA Clearance Of Its IND For LYL845
Brief: Lyell Immunopharma Reports Second Quarter Financial Results And Business Highlights
Brief: Lyell Immunopharma Inc Files For Potential Mixed Shelf Offering
Brief: Lyell Immunopharma Appoints Gary Lee As Chief Scientific Officer
Brief: Lyell Announces FDA Clearance Of IND For LYL132
Brief: Lyell Immunopharma Says Entered Into Second Amendment To Collaboration And License Agreement With GSK
Brief: Lyell Immunopharma Announces FDA Clearance Of Its IND For LYL797
Brief: Lyell Immunopharma Announces CGMP Qualification Of Lyfe Manufacturing Center
Brief: Lyell Posts Quarterly Revenue $2.8 Million
Brief: Lyell Immunopharma Says Board Chair To Take Temporary Medical Leave Of Absence
Lyell Immunopharma Inc reports results for the quarter ended in June - Earnings Summary
Brief: Lyell Immunopharma Reports Second Quarter 2021 Financial Results And Business Highlights
U.S. RESEARCH ROUNDUP- American Express, Rocket Companies, Walkme